3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Dermatologic
2
Gastrointestinal
1
Breast
1
Conditions
Melanoma
2
Pancreatic Neoplasms
1
Lung Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
58
Ipilimumab
53
Cyclophosphamide
53
Nivolumab
45
aldesleukin
35
Interleukin-2
26
fludarabine phosphate
22
fludarabine
21
Vemurafenib
20
Temozolomide
19
Radiotherapy
19
dabrafenib
15
trametinib
12
Radiosurgery
11
CTLA-4 Antigen
11
spartalizumab
10
Filgrastim
10
Dacarbazine
10
cobimetinib
9
binimetinib
9
atezolizumab
9
Biopsy
9
poly ICLC
8
Paclitaxel
8
Antilymphocyte Serum
8
encorafenib
7
avelumab
7
Rituximab
7
Introns
7
romidepsin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
1-methyltryptophan
×
Dermatologic
×
Clear all
NCT03301636
2022-09-27
NLG2107
Lumos Pharma
Phase 2
Terminated
21 enrolled
11 charts
NCT00739609
2020-05-28
D-1MT
Lumos Pharma
Phase 1
Terminated
17 enrolled